North America Wound Debridement Products Market – Insights
Wound debridement is the process of removing dead tissue from wounds. Biological debridement, enzymatic debridement, autolytic debridement, and mechanical debridement are some of the types of wound debridement. Hydrotherapy, wet-to-dry dressing, and monofilament debridement pads are the types of mechanical debridement.
North America wound debridement products market is estimated to account for US$ 223.4 Mn in terms of value in 2019 and is expected to reach US$ 378.3 Mn by the end of 2027.
North America Wound Debridement Products Market: Drivers
Increasing cases of injuries/ trauma are expected to propel growth of North America wound debridement products market. For instance, according to January 2018 factsheet of the World Health Organization, 20–30% of older people who fall suffer moderate to severe injuries such as bruises, hip fractures, or head trauma, in the U.S.
Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, geriatric population in the U.S. is expected to reach 77 million by 2035.
U.S. held dominant position in North America wound debridement products market in 2018, accounting for 88.1% share in terms of value, followed by Canada.
North America Wound Debridement Products Market: Restraints
Surgical debridement and mechanical debridement have a higher risk for bleeding and peri-procedural pain, which limits their adoption, thereby hindering growth of the market.
Moreover, lack of standard usage guidelines and trained manpower is also expected to limit growth of the market. Usage of devices such as hydrosurgical debridement devices, low frequency ultrasound, and surgical wound debridement lack standard guidelines and usage indications for various disorders. There is also lack of trained professionals to guide patients in the usage of these devices for different conditions in the long-term treatment plan.
North America Wound Debridement Products Market: Opportunities
Market players need to develop and introduce affordable sophisticated systems with easy-to-operate features to boost adoption of wound debridement products in homecare settings.
Moreover, improved reimbursement rates for wound debridement products is also expected aid in growth of the market. Wound debridement products used at home are covered under Medicare Part – B.
Chronic ulcers segment in North America wound debridement products market was valued at US$ 88.4 Mn in 2018 and is expected to reach US$ 175.1 Mn by 2027 at a CAGR of 8.2% during the forecast period.
Market Trends/Key Takeaways
American Society of Plastic Surgeons (ASPS) emphasizes on debridement in case of severe infections. Physicians in the U.S. recommend the use of appropriate and safe forms of debridement where the autolytic is safe. The demand of small debridement equipment such as scalpel and enzymatic solutions is also high in the market.
Increasing prevalence of diabetes in the U.S is leading to high demand for wound debridement products. For instance, according to International Diabetes Federation’s IDF Diabetes Atlas 2019 Edition, the numbers of adults with diabetes in the U.S. was 31.0 million.
- Delegation of Duties
- The term “wound debridement” as used in section 12-41-113(3), C.R.S., refers to sharp, enzymatic, selective, and pharmacological wound debridement and can only be performed by a licensed physical therapist unless otherwise authorized by Colorado law. A physical therapist may not delegate such wound debridement to unlicensed personnel, but may delegate soft or nonselective wound debridement to a physical therapist assistant.
- Supervision of Physical Therapist Assistants
- the physical therapist may supervise the physical therapist assistant performing all acts that are included in the practice of physical therapy as defined in § 12-41-103(6), C.R.S., except for the therapies and procedures identified in Rule 1(D) above or acts that are otherwise prohibited by law. Physical therapist assistants may perform soft or non-selective wound debridement as noted in Rule 1(E), but may not perform sharp, enzymatic, selective, and pharmacological wound debridement
Value Chain Analysis
North America Wound Debridement Products Market: Competitive Landscape
Major players operating in North America wound debridement products market include, Smith & Nephew plc, Zimmer Biomet, DeRoyal Industries, Inc., Lohmann & Rauscher International, Arobella Medical, LLC, Bactiguard AB, MediWound Ltd., Misonix, Inc., Söring GmbH, BSN Medical, and Derma Sciences Inc.
North America Wound Debridement Products Market: Key Developments
Major players in the market are focused on adopting M&A strategies to expand their product portfolio. For instance, in March 2020, Bactiguard AB acquired Vigilenz Medical Devices and Vigilenz Medical Supplies.
Major players in the market are also focused on conducting clinical trials to expand their product portfolio. For instance, in December 2019, MediWound Ltd. initiated Phase 2 clinical study of EscharEx, a topical biologic drug candidate designed to enzymatically debride chronic wounds, for the treatment of venous leg ulcers.